<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03585530</url>
  </required_header>
  <id_info>
    <org_study_id>huaianzhuweiguo1</org_study_id>
    <nct_id>NCT03585530</nct_id>
  </id_info>
  <brief_title>Raltitrexed Concurrent With Radiotherapy for Elderly Chinese Patients With Squamous Cell Carcinoma of Esophagus</brief_title>
  <official_title>Raltitrexed Concurrent With Radiotherapy for Elderly Chinese Patients With Squamous Cell Carcinoma of Esophagus: A Phase-II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huai'an First People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huai'an First People's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Concurrent chemoradiotherapy is one of the curative options for esophageal squamous cell
      carcinoma. We evaluated the efficacy and toxicity of raltitrexed with concurrent radiotherapy
      in elderly patients with esophageal cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 5, 2018</start_date>
  <completion_date type="Anticipated">July 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>3 years</time_frame>
    <description>From the date of randomization until the date of death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>3 years</time_frame>
    <description>From the date of randomization to the date of first observation of disease progression, or relapse, or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>treatment-related toxicities</measure>
    <time_frame>From the date of randomization until six months after treatment completion</time_frame>
    <description>Toxicities were graded according to the National Cancer Institute Common Toxicity Criteria (NCICTC), version 3.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life(QOL)</measure>
    <time_frame>3 years</time_frame>
    <description>QOL is respectively evaluated at randomization and 1 month, 3 month, 6 month and yearly after treatment among patients by using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C-30 (EORTC QLQ-C30)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Esophagus Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>raltitrexed</intervention_name>
    <description>Raltitrexed 2.6mg/m2 was administered on d1、d22</description>
    <arm_group_label>treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Histological or cytologic diagnosis of esophageal carcinoma. ECOG performance status 0-1.
        Age:70-85 years. Joined the study voluntarily and signed informed consent form Patients
        must not have received any prior anticancer therapy.

        Stage IIa-Ⅳa(AJCC 2002). Target lesions can be measured according to RECIST criteria. No
        serious system dysfunction and immuno-deficiency, Adequate organ function including the
        following: Hemoglobin ≥9 g/dL, WBC≥3x109/L, Neutrophils (ANC )≥1.5x109/L, platelet count
        ≥100x 109/L, TBIL&lt;1.5 x ULN, ALT and AST ≦ 2.5 x ULN, creatinine ≦ 1.5 x ULN.

        Exclusion Criteria:

        Multiple carcinomas of the esophagus. Biopsy-proven invasion of the tracheobronchial tree
        or tracheoesophageal fistula.

        Metastatic disease (M1b). A primary tumor that extended to within 2 cm of the
        gastroesophageal junction. Prior chemotherapy, prior thoracic radiation, surgical resection
        of the primary tumor.

        history of a second malignancy other than nonmelanoma skin cancer.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>wei-guo Zhu, MD</last_name>
    <phone>+861351155000</phone>
    <email>jshazwg@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Huai'an First Hospital</name>
      <address>
        <city>Huai'an</city>
        <state>Jiangsu</state>
        <zip>223300</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>wei-guo zhu, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>July 1, 2018</study_first_submitted>
  <study_first_submitted_qc>July 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2018</study_first_posted>
  <last_update_submitted>January 7, 2019</last_update_submitted>
  <last_update_submitted_qc>January 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Esophageal neoplasma</keyword>
  <keyword>adjuvant therapy</keyword>
  <keyword>raltitrexed</keyword>
  <keyword>radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltitrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

